Trial Profile
A Phase II Study of VEGF-Trap [afilbercept] in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Gynaecological cancer; Soft tissue sarcoma
- Focus Therapeutic Use
- 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Nov 2006 Status change
- 21 Nov 2006 New trial record.